When Your Client Needs a Medication Outside Our Formulary: A Guide for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | April 3, 2025 | 8 min read

Pharmacy lien formularies aren't ceilings — they're starting points. When your client's prescriber specifies a medication outside the standard list, a non-formulary exception process can cover it. Here's how it works, what you need to do, and why formulation specificity is clinical necessity worth documenting.

When Your Client Needs a Medication Outside Our Formulary: A Guide for PI Attorneys

Most pharmacy lien engagements run on autopilot. A physician prescribes gabapentin, cyclobenzaprine, or meloxicam — medications that appear in virtually every personal injury pharmacist's standard formulary — and the lien program handles the rest. But not every personal injury patient fits the standard template.

Some clients are prescribed medications that fall outside a lien program's standard list: prescription medical foods, compounded formulations, specialty biologics, or brand-specific products required because of a patient's allergy profile. When that happens, attorneys sometimes assume the medication simply can't be covered — and leave their client without access to a therapy their doctor specifically prescribed.

That assumption is wrong. Here's what you actually need to know.

[!KEY] A pharmacy lien formulary is a workflow tool, not a hard coverage limit — medications outside the standard list can often be covered through a non-formulary exception with physician documentation and attorney acknowledgment.

What "Formulary" Means in a Pharmacy Lien Program

The term "formulary" carries specific meaning in the insurance world: it's the list of drugs a plan will cover, and medications outside it typically require extensive prior authorization or simply aren't available. Attorneys who encounter a pharmacy lien formulary sometimes apply that same mental model — and conclude that non-formulary means uncoverable.

A pharmacy lien formulary is different. It's a pre-vetted list of medications that the lien program can approve and dispense quickly, without additional review. The standard formulary exists as a workflow tool, not as a hard coverage limit. It reflects the medications most commonly prescribed in PI cases — which means it covers the vast majority of clients without friction.

What it does not mean is that everything outside the list is off the table.

For medications outside the standard formulary, most reputable lien programs have an exception process. At LienScripts, we call it the non-formulary exception: with clinical necessity documentation from the prescribing physician and a written acknowledgment from the attorney of record, we can source and cover medications that aren't on our standard list — including prescription medical foods, compounds, and formulation-specific products.

Why Some Clients Need Medications Outside the Standard Formulary

Several categories of medications fall outside standard PI pharmacy formularies by default:

Prescription medical foods. Metanx, Deplin, Cerefolin, and similar products are prescribed by physicians but regulated by the FDA as medical foods rather than drugs. They require a prescription and are clinically indicated for specific conditions, but they exist in a regulatory category that standard formularies don't cover — because standard formularies are built around pharmaceutical drugs. For clients with TBI-related neuropathy, diabetic-overlap peripheral nerve conditions, or MTHFR-related folate metabolism issues, these products may be specifically indicated. See our overview of Metanx for nerve damage for a worked example of how this situation arises.

Compounded medications. Custom compounded formulations — topical pain creams, specific dose combinations, allergen-excluded preparations — are prescribed when commercially available alternatives are insufficient or contraindicated. These are common in PI cases involving complex pain presentations, dermal sensitivities, or dosing requirements that don't match available commercial products. See our guide to compound medications in personal injury cases for more detail.

Brand-specific formulations required by allergy profile. This is the category that surprises most attorneys. When a patient has documented sensitivities to inactive ingredients — dyes, titanium dioxide, shellfish-derived excipients, wheat starch fillers — a prescriber may specify a particular branded product not because it's more expensive or more prestigious, but because it is the only available formulation that patient can safely take. A generic "equivalent" may be therapeutically identical in active ingredient but clinically inappropriate if it contains a documented allergen.

Specialty medications for unusual injury presentations. Some traumatic injuries produce conditions that require medications outside the typical PI medication set — biologics for inflammatory injury complications, specialized anticonvulsants for post-traumatic seizure, or FDA-approved drugs rarely prescribed in PI contexts but clinically appropriate for a specific patient.

The Non-Formulary Exception Process — Step by Step

The process is simpler than it sounds. There are four steps:

Step 1: Prescribing physician documents clinical necessity. The prescriber provides documentation explaining why this specific medication (and in some cases, this specific formulation) is medically indicated for this patient. For allergy-driven formulation specificity, the documentation should explicitly reference the patient's allergy profile and explain why standard alternatives are contraindicated. This letter becomes part of the patient's file and will be referenced in the POGOS report if applicable.

Step 2: Attorney reviews and acknowledges in writing. The attorney of record provides written confirmation that the non-formulary medication is included in the lien agreement. This is a brief, straightforward communication — not a separate legal document, not a liability assumption. It simply confirms that the medication is part of the covered lien scope.

Step 3: LienScripts confirms coverage and sources the medication. Once we receive the physician's documentation and the attorney acknowledgment, we confirm coverage — typically within two business days — and arrange for the medication to be dispensed to the patient. There is no upfront cost to the patient. The coverage structure is identical to any other lien medication.

Step 4: Patient receives the medication and ongoing management continues. Refills, documentation, and clinical oversight proceed the same way as any other lien medication. Non-formulary status doesn't create a different track — it just requires the initial acknowledgment and documentation to get started.

[!KEY] The physician's medical necessity letter for a non-formulary exception does double duty — it unlocks lien coverage and simultaneously creates the clinical documentation that preempts defense challenges to that medication at settlement, making the letter worth requesting early and preserving carefully in the case file.

[!NOTE] When a prescriber specifies a brand formulation because of a patient's documented allergy to inactive ingredients in generics, that choice is clinical necessity — document it explicitly in the physician letter and POGOS report to preempt defense challenges at settlement.

When Formulation Specificity Is Clinical Necessity

This is a point worth dwelling on, because it has direct implications for how you document your client's case.

In pharmaceutical and pharmacy law, medications are not always interchangeable even when the active ingredient is identical. Inactive ingredients — dyes, fillers, excipients, capsule materials, coating agents — can trigger allergic reactions, intolerances, or contraindicated interactions in some patients. A prescriber who specifies Metanx FC rather than a generic B-vitamin complex, or a particular compounded cream rather than a commercially available topical, may be doing so entirely on the basis of the patient's documented allergy or intolerance profile.

When this is the case, the formulation specificity is not a brand preference. It is a clinical necessity. And it should be documented as such.

Practically, this means:

• The prescriber's medical necessity letter should explicitly reference the allergy or intolerance profile and state that the specified formulation is required because standard alternatives contain ingredients the patient cannot safely receive
• The patient's allergy documentation in the medical record should be consistent with the prescription
• The POGOS report should reflect the prescriber's rationale for the specific formulation choice

This documentation doesn't just support the non-formulary coverage request — it also protects the medication claim at settlement. Defense counsel reviewing a non-standard medication in the demand is much less likely to challenge a therapy with explicit documented medical necessity, physician rationale, and clear allergy-based contraindication of alternatives.

For a real example of how this played out in a TBI case involving Metanx FC, read our case study on non-formulary coverage for a patient with a complex allergy profile.

How Non-Formulary Medications Are Documented at Settlement

Non-formulary medications are included in the demand package the same way as any other lien medication — but with one additional layer of documentation: the prescriber's medical necessity letter.

In the POGOS report, the clinical pharmacist narrative will reference the specific medication, the physician's documented rationale, and (where applicable) the allergy profile that required the specific formulation. This clinical narrative is the foundation for defending the medication in the demand. A well-documented non-formulary medication is no more vulnerable to defense challenge than any other prescription medication with a clear clinical rationale.

For compounded medications specifically, there are additional best practices — see our compound medications guide for documentation strategy specific to that category.

Post-Settlement Continuity: Thinking Beyond the Case

Some non-formulary medications — particularly prescription medical foods like Metanx for TBI-related neuropathy — are long-term therapies. The patient who needs Metanx today may need it for years after the settlement closes. That's a continuity problem the lien program typically doesn't address.

At LienScripts, we take a different approach for clients on long-term therapies. Before the case closes, we work to connect the patient with post-settlement resources: manufacturer patient assistance programs, GoodRx and discount programs, and cash-pay specialty pharmacies that routinely carry the medication. The goal is to ensure the patient has a viable path to continuing their medication after the lien is resolved — not just during the litigation period.

This matters for your client relationship too. An attorney who can tell a client "we've made sure you'll be able to continue your medication after the case closes" is providing a level of service that most firms don't offer. It's the kind of detail that generates referrals.

[!KEY] For clients on long-term non-formulary medications like Metanx, proactively connecting them with post-settlement access resources before the case closes demonstrates that the attorney protected more than just the settlement check — it is a client relationship differentiator that most PI firms do not offer.

Related Resources

• What Is Metanx? A Prescription Medical Food for Nerve Damage
• Case Study: TBI Patient Accesses Metanx Through a Pharmacy Lien
• Compound Medications in Personal Injury Cases
• Prior Authorization Workarounds for Personal Injury Patients
• For Attorneys: How LienScripts Works
• How It Works